pre-update Archives

On-Demand Webinar

Physiologically-Based Pharmacokinetic Modeling & Simulation to Support Asciminib NDA Submission & Inform Drug Product Label

Physiologically based pharmacokinetic (PBPK) modeling and simulation has become an established approach to assess drug-drug…

CertaraJanuary 13, 2023

Announcement

Certara Awarded NIH Contract for Toxicology Consulting Support

Certara toxicology experts to support NIH’s BPN and HEAL drug development programs for nervous system…

CertaraJanuary 10, 2023

Video

If your drug is a CYP3A substrate, we have good news for you!

CertaraJanuary 9, 2023

Announcement

Ghent University wins the 2021/22 Certara-Simcyp Grant and Partnership Scheme

PRINCETON, N.J., January 9, 2023 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation,…

CertaraJanuary 9, 2023

White Paper

Drug interactions with therapeutic proteins, regulatory expectations and modeling and simulation approaches

CertaraJanuary 3, 2023

Blog

New FDA Requirement to Support Labeling on DDIs in the Pediatric Population

The effects of drug-drug interactions (DDIs) could differ in the pediatric population compared to adults.…

CertaraDecember 21, 2022

Blog

The Phoenix Workflow Shortcuts Every Pharmacokineticist Needs

Certara’s Phoenix™ Pharmacokinetic and Pharmacodynamic (PK/PD) Platform can revolutionize your pharmaceutical organization’s approach to PK/PD…

CertaraDecember 16, 2022

Press Release

Certara Announces the Completion of Arsenal Capital Partners’ Investment and the Appointment of David Spaight to the Board of Directors

Arsenal closed the previously announced $449M stock purchase from funds controlled by EQT Private Equity…

CertaraDecember 8, 2022

On-Demand Webinar

Therapeutic Proteins’ Drug-Drug Interactions: Updates & Challenges

Therapeutic proteins (TP) - and more specifically monoclonal antibodies - are part of the therapeutic…

CertaraDecember 5, 2022

Brochure

BaseCase Portal

CertaraNovember 30, 2022

pre-update